Personal tools
You are here: Home / Labs / Animal Cell Technology Unit / Invited Speakers

Invited Speakers

Invited Speakers


Prof Dr Joost Sluijter

Therapeutics for myocardial repair – moving forward?

September 14th 2018


Dr. Jörg Weiske

Head of Protein Technologies 1, Research & Development, Pharmaceuticals at Bayer AG

Cellular Thermal Shift Assay (CETSA) - Case study @ Protein Technologies (Bayer AG)

May 17th 2018


Professor Tom L. Blundell

Cambridge University, UK

Structure-guided Fragment-based Drug Discovery for Cancer and Tuberculosis: Fighting the Emergence of Resistance


Prof. Alois Jungbauer

Department of Biotechnology, BOKU, Vienna, Austria

Separation and Quantification of Virus-like Particles from other extra cellular particles

March 15th 2018


David Naveh

Ph.D., MBA, CEO Hemogem, ex- VP and ex-CTO of Bayer Biological Products Worldwide

Development of Biological Therapeutics for Health and Financial Value Creation - The Pharma Perspective

March 7th 2018


Monique M. van Oers

Laboratory of Virology, Wagninngen University, the Netherlands

Proteins Required for Baculovirus Particle Formation: Relevance for the Development of a Baculovirion-Free Expression System

March 7th 2018


Professor Mike Betenbaugh

Johns Hopkins University, USA

Glycoengineering in CHO cells: Glyco Control-Inside and Out

February 5th 2018


Andreas Busch

Head of Drug Discovery - Bayer Pharmaceuticals

Addressing unmet medical needs: Key drivers for Drug Discovery at Bayer

January 8th 2018


Dr. Manel Cascalló

VCN Biosciences SL, Spain

Oncolytic adenoviruses expressing hyaluronidase: from bench to patients

January 8th 2018


Dr. Eda Machado

St. Jude Children's Research Hospital, Memphis, Memphis, Tennessee USA

Regulated lysosomal exocytosis, an unconventional pathway in cancer progression

January 8th 2018


Dr. Andreas Wilmen

Protein Engineering & Assays 2, Bayer AG

Cardiovascular Research at Bayer

January 8th 2018


Dr Hansjörg Hauser

Department of Scientific Strategy, Helmholtz Centre for Infection Research (HZI)

Viral defence by interferons: A closer look to single cells in populations

January 8th 2018


William M. Miller

Chemical and Biological Engineering, Northwestern University Evanston, USA

A Uniform-Shear-Rate Microfluidic Bioreactor for Real-Time Analysis of Proplatelet Formation and Rapidly-Released Platelets

June 21st 2017


Alain Bernard

Biopharma Executive Advisor, Independent advisor to pharma executives · Institut National Agronomique Paris-Grignon

Knowledge Management

April 12th 2017


Felipe Prosper

Director of Hematology and Cell Therapy, Clinica Universidad de Navarra

Drug and cell delivery systems for cardiac repair

February 7th 2017


Simone Kardinahl

Head of Cell & Protein Sciences, Biologics Research, Bayer AG

DD Biologics – an overview on challenges and opportunities

January 31st 2017


Brian Murphy

Celgene Cellular Therapeutics, USA

Quality by Design and Phase Appropriate Development for Cell Therapies

November 28th 2016


Thorsten Lorenz

Novartis Pharma AG, Basel, Switzerland

Developability Assessment of therapeutic Antibodies - A concept for early Lead Selection

May 31st 2016


Katey Owen

Deputy Director for Vaccines Development (CMC), Bill & Melinda Gates Foundation

Vaccine development and manufacturing for those most in need of vaccines

April 29th 2016


Philippe Couttet

Novartis Institutes of Biomedical Research in Basel, Switzerland

microRNAs as biomarker of drug-induced tissue injury

December 3rd 2015


Uwe Marx

CEO, TissUse GmbH

“Humans-on-a-chip” – a paradigm shift in substance testing?!

November 17th 2015


Eytan Abraham

Head of Cell Therapy Research & Technology, Lonza, USA

Stem Cells and Cell Therapy at LONZA

July 13th 2015


Hitto Kaufmann

Vice President Technology and Development
Sanofi Biologics, Germany

Innovation in Biologics Manufacturing

May 27th 2015


Thomas Pietzonka

NIBR Biologics Center, Basel

Changing the Practice of Medicine - Novartis Institutes for Biomedical Research

May 4th 2015


Matthias Frech


Biophysical Methods in Drug Discovery: Combination is Key
The Project Kinetics for Drug Discovery

February 27th 2015


Roger-Marc Nicoud


The amazing ability of continuous chromatography to adapt to a moving environment

February 12th 2015


Carlos Augusto Pereira

Instituto Butantan, Laboratorio de Imunologia Viral, São Paulo, Brazil

Vectors carrying heterologous RNA for designing new viral vaccines

October 23rd 2014


Christof von Kalle, MD, PhD

National Center for Tumor Diseases (NCT), Heidelberg

Translational Oncology – the National Center for Tumor Diseases

October 17th 2014


Rene Hoet, Heiner Apeler, Lars Linden, Beate Müller-Tiemann

BAYER HEALTHCARE, Global Biologics, Germany

Protein Biopharmaceuticals @ Bayer:
From Discovery to Development

July 3rd 2014


Vish Nene


The ILRI Vaccine Biosciences program and improved vaccines for the control of East Coast fever in cattle

May 16th 2014


Marc Peschanski

I-STEM (INSERM/UEVE 861, AFM), Evry – France

Harnessing pluripotent stem cells for pharmacology

July 18th 2013


Muntasir Mamun Majumder

FIMM, Institute for Molecular Medicine Finland

An individualized system medicine platform to guide treatment decisions for therapy-resistant Acute Myeloid Leukemia

June 21st 2012


Joachim Klein

Technische Universtat Braunschweig, Germany (jUb.)

President, Braunschweig Academy of Sciences, Germany

Not all chemicals are created equal: The potential of biobased processes and products

June 1st 2012


John G. Aunins

Visiting Professor, ITQB

Merck Sharp & Dohme, West Point, New Jersey, USA

Some Perspectives on Vaccines, Biologicals, and the Pharmaceutical Industry

November 15th 2011


Uwe Marx & Mark Rosowski

Technische Universität Berlin, Institute of Biotechnology - Department of Medical Biotechnology

Vascularized multi-organ systems – the next level of engineering human biology in vitro

August 4th 2011


Isabelle Knott

Director, Head of Cell Culture Development

GlaxoSmithKline Biologicals S.A., Rixensart, Belgium

Cervarix: first human vaccine manufactured with baculovirus expression system

July 12th 2011


Héla Kallel

Head, Bioprocess Development Unit

Institut Pasteur de Tunis - 13, place Pasteur. BP 74. 1002 Tunis

Bioprocess development activities at Institut Pasteur of Tunis

June 28th 2011


Regina Grillari, PhD

Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria

The importance of peeing earnest: urine derived cells as model systems in biology and biomedicine

June 17th 2011


Christian Manzke & Etienne Evrard MD

Sartorius Stedim Biotech GmbH – B. Braun AG -Goettingen / Melsungen

Bioprocess integrated solutions

Abril 27th 2011


Brian Lee MD

President, PBS Biotech, Inc

PBS Biotech, Inc - California, EUA

Mixing methodologies in single use bioreactors - A comparative analysis of consistency across scale

Abril 4th 2011


Aleš Štrancar MD PhD

BIA Separations, Teslova 30, SI-1000 Ljubljana

Monolithic chromatography supports – technology platform for the analysis and production of new generation of drug candidates like plasmid DNA and viral vector particles

March 21st 2011


Wilfried Bakker MD

Netherlands Vaccine Institute (NVI/RIVM)

Development and Technology Transfer for Viral Vaccines

March 15th 2011


Leo van der Pol MD PhD

Netherlands Vaccine Institute (NVI/RIVM)

Overview of Vaccine Process Development at RIVM

March 15th 2011


Marc Peschanski MD

Scientific Director, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-STEM, INSERM/UEVE) Evry, France

Pathological modeling, drug discovery and toxicity testing using pluripotent stem cells

March 2nd 2011


Leo van der Pol MD

Overview of Vaccine Process Development at RIVM



Nigel Jenkins

National Institute for Cellular Biotechnology, Ireland

Quality considerations for the production of biopharmaceuticals

February 2nd 2010


Hagen von Briesen

Fraunhofer-Institute for Biomedical Engineering

Global HIV Vaccine Research Cryorepository - GHRC

January 29th 2010


Judy Lieberman

Immune Disease Institute and Program in Cellular and Molecular Medicine, Children’s Hospital Boston, Dept of Pediatrics, Harvard Medical School

Micromanaging cell growth and differentiation

December 16th, 2009


Octavio T. Ramírez

Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología Universidad Nacional Autónoma de México

Bioreactor Scale-Down Studies of Temperature-Inducible Recombinant Protein Production in E. coli

November 23th, 2009


Kenneth Lundstrom

PanTherapeutics, Lausanne, Switzerland

Viral Vectors in Gene Therapy: Special Emphasis on Alphaviruses

March 11th, 2009


Kenneth Lundstrom

PanTherapeutics, Lausanne, Switzerland

Expression of GPCRs in Drug Discovery and Structural Biology

March 10th, 2009


Catherine Brenner Jan, DR CNRS

Faculté de Pharmacie, Lausanne, Switzerland

Signalisation et physiopathologie cardiaque INSERM U769

February 2009


Anna Price

In vitro Toxicology Unit,  European Centre for the Validation of Alternative Methods,  Institute of Health and Consumer Protection, European Commission Joint Research Centre, Ispra (VA), Italy

Re-aggregated brain cell culture as a sensitive in vitro model to evaluate developmental/adult neurotoxicity: application for regulatory requirements

October 28th, 2008


Dr. Ing. Reiner Luttmann

Hamburg University of Applied Sciences, Research Center of Bioprocess Engineering and Analytical Techniques

A comprehensive study in optimal production of Active Pharmaceutical Ingredients with Pichia pastoris

September 12th, 2008


Manuel Cánovas

Department of Biochemistry and Molecular Biology B. Faculty of Chemistry. University of Murcia

Bioprocess Optimization By Using Systems Biology

September 11th, 2008


Matthew Croughan

Amgen Bioprocessing Center

Keck Graduate Institute (KGI), Claremont, CA

The Silver Anniversary of Clinical Protein Production from Recombinant CHO Cell Culture

June 9th, 2008


Carlos A. Pereira

Univ. Strasbourg, França and Instituto Butantan, Brasil

Approaches for preparation of viral antigens from mammalian and insect cells


John Aunins

MERCK & CO, Philadelphia, EUA and ITQB/UNL, Portugal

Adenovirus-vectored HIV vaccine development


Hansjörg Hauser

GBF and Univ. Braunschweig, Germany

Cancer immune therapy using genetically modified dendritic cells


Eric J. Kremer, CNRS-UMR, France


Ursula Sonnewald, Pharmacology & Toxicology Medical School Trondheim, Norway


Uwe Gottschalk, Sartorius AG, Germany


Heiko Zimmermann, Fraunhofer IBMT, Germany


Catherine Brenner, CNRS-UMR, France


Kenneth Lundstrom, PanTherapeutics, Switzerland


Brian Kelley, Genentech, USA


Laura Palomares, México


Document Actions